Figure 2
Figure 2. LPS-induced DC migration toward CCL19/MIP-3β is impaired by sorafenib. DCs were generated by incubating adherent monocytes with GM-CSF and IL-4. On day 5 of culture, cells were exposed for 24 hours to sorafenib (A,B) or sunitinib (C) at the indicated concentrations. LPS (100 ng/mL) was added as a stimulus to the culture media for the last 24 hours. (A) Migration toward CCL19 was analyzed using transwell chambers. DCs (105) were seeded in the upper chamber in triplicates, and the number of migrated DCs was analyzed after 4 hours by counting gated DCs for one minute by FACS analysis (*P < .05, **P < .001). (B,C) Surface expression of CCR7 was analyzed by staining of DCs with FITC conjugated antibodies against CCR7 and measuring by FACS analysis. Numbers represent mean fluorescence intensity.

LPS-induced DC migration toward CCL19/MIP-3β is impaired by sorafenib. DCs were generated by incubating adherent monocytes with GM-CSF and IL-4. On day 5 of culture, cells were exposed for 24 hours to sorafenib (A,B) or sunitinib (C) at the indicated concentrations. LPS (100 ng/mL) was added as a stimulus to the culture media for the last 24 hours. (A) Migration toward CCL19 was analyzed using transwell chambers. DCs (105) were seeded in the upper chamber in triplicates, and the number of migrated DCs was analyzed after 4 hours by counting gated DCs for one minute by FACS analysis (*P < .05, **P < .001). (B,C) Surface expression of CCR7 was analyzed by staining of DCs with FITC conjugated antibodies against CCR7 and measuring by FACS analysis. Numbers represent mean fluorescence intensity.

Close Modal

or Create an Account

Close Modal
Close Modal